Search research articles
Contact Us
Filters
Showing results (71-80 of 119) with videos related to
Page
of 12
Sort By:
Melanoma Research
|
February 23, 2023
Recurrent hemophagocytic lymphohistiocytosis in advanced melanoma treated with two different BRAF/MEK-inhibitor regimens
Jean-Baptiste Le Goubey, Marion Sassier, Ines Nakouri, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 16, 2018
Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer
Benjamin Houdu, Charline Lasnon, Idlir Licaj, et al.
EJNMMI Research
|
February 9, 2021
A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers
Nicolas Aide, Laurent Poulain, Nicolas Elie, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 3, 2021
EANM guideline on the role of 2-[<sup>18</sup>F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA)
Roberto C Delgado Bolton, Nicolas Aide, Patrick M Colletti, et al.
Molecular Imaging and Biology
|
December 4, 2014
NEMA NU 4-Optimized Reconstructions for Therapy Assessment in Cancer Research with the Inveon Small Animal PET/CT System
Charline Lasnon, Audrey Emmanuelle Dugue, Mélanie Briand, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 12, 2018
Correction to: Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer
Benjamin Houdu, Charline Lasnon, Idlir Licaj, et al.
Molecular Imaging and Biology
|
October 14, 2017
Uptake of Radium-223 Dichloride and Early [<sup>18</sup>F]NaF PET Response Are Driven by Baseline [<sup>18</sup>F]NaF Parameters: a Pilot Study in Castration-Resistant Prostate Cancer Patients
Arthur Letellier, Alison C Johnson, Nicolas How Kit, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 8, 2003
Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT
Nicolas Aide, Olivier Cappele, Philippe Bottet, et al.
European Radiology
|
March 28, 2022
Interpretation of 2-[<sup>18</sup>F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors
Guillaume Manson, Amaeshi Chukwunonye Lemchukwu, Fatima-Zohra Mokrane, et al.
Molecular Imaging and Biology
|
June 11, 2008
Usefulness of automatic quantification of immunochemical staining on whole tumor sections for correlation with oncological small animal PET studies: an example with cell proliferation, glucose transporter 1 and FDG
Nicolas Aide, Alexandre Labiche, Paulette Herlin, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 119) with videos related to
Sort By:
Page
of 12
Melanoma Research
|
February 23, 2023
Recurrent hemophagocytic lymphohistiocytosis in advanced melanoma treated with two different BRAF/MEK-inhibitor regimens
Jean-Baptiste Le Goubey, Marion Sassier, Ines Nakouri, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 16, 2018
Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer
Benjamin Houdu, Charline Lasnon, Idlir Licaj, et al.
EJNMMI Research
|
February 9, 2021
A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers
Nicolas Aide, Laurent Poulain, Nicolas Elie, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 3, 2021
EANM guideline on the role of 2-[<sup>18</sup>F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA)
Roberto C Delgado Bolton, Nicolas Aide, Patrick M Colletti, et al.
Molecular Imaging and Biology
|
December 4, 2014
NEMA NU 4-Optimized Reconstructions for Therapy Assessment in Cancer Research with the Inveon Small Animal PET/CT System
Charline Lasnon, Audrey Emmanuelle Dugue, Mélanie Briand, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 12, 2018
Correction to: Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer
Benjamin Houdu, Charline Lasnon, Idlir Licaj, et al.
Molecular Imaging and Biology
|
October 14, 2017
Uptake of Radium-223 Dichloride and Early [<sup>18</sup>F]NaF PET Response Are Driven by Baseline [<sup>18</sup>F]NaF Parameters: a Pilot Study in Castration-Resistant Prostate Cancer Patients
Arthur Letellier, Alison C Johnson, Nicolas How Kit, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 8, 2003
Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT
Nicolas Aide, Olivier Cappele, Philippe Bottet, et al.
European Radiology
|
March 28, 2022
Interpretation of 2-[<sup>18</sup>F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors
Guillaume Manson, Amaeshi Chukwunonye Lemchukwu, Fatima-Zohra Mokrane, et al.
Molecular Imaging and Biology
|
June 11, 2008
Usefulness of automatic quantification of immunochemical staining on whole tumor sections for correlation with oncological small animal PET studies: an example with cell proliferation, glucose transporter 1 and FDG
Nicolas Aide, Alexandre Labiche, Paulette Herlin, et al.
Page
of 12